Arena Pharmaceuticals, Inc. (ARNA) Posts Q2 Loss of 12c/Share, Wider than Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $22 million versus the consensus estimate of $7.38 million.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Liberty Media Corporation Announces Third Quarter Earnings Release and Conference Call
- Byrna Technologies Inc. (BYRN) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
